Human recombinant tissue transglutaminase ELISA: An innovative diagnostic assay for celiac disease

D. Sblattero, I. Berti, C. Trevisiol, R. Marzari, A. Tommasini, A. Bradbury, A. Fasano, A. Ventura, T. Not

Research output: Contribution to journalArticle

208 Citations (Scopus)

Abstract

OBJECTIVE: Tissue transglutaminase is the autoantigen recognized by the sera of celiac patients. An enzyme-linked immunosorbent assay (ELISA) based on guinea-pig tissue transglutaminase was recently used to measure serum tissue transglutaminase antibodies for the diagnosis of celiac disease. We determine the sensitivity and specificity of an ELISA test based on the use of human recombinant transglutaminase, compared with the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies. METHODS: Serum samples were tested from 65 patients with intestinal biopsy proven celiac disease, from 10 patients with Crohn's disease, and from 150 healthy blood donors. RESULTS: Human transglutaminase ELISA identified 64 of 65 celiac patients, whereas the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies identified 58 of 65 and 60 of 65 subjects, respectively. The three tests showed comparable specificity. CONCLUSIONS: These results proved that the human tissue transglutaminase-based ELISA represents a cost-effective strategy for identifying both symptomatic and atypical forms of celiac disease and could mean that intestinal biopsy need no longer be the gold standard for diagnosing this clinical condition. Furthermore, early identification and treatment of patients with celiac disease in an outpatient setting could have significant implications for reducing long-term morbidity and can produce major savings in future health care costs. (C) 2000 by Am. Coll. of Gastroenterology.

Original languageEnglish
Pages (from-to)1253-1257
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume95
Issue number5
DOIs
Publication statusPublished - May 2000

Fingerprint

Celiac Disease
Transglutaminases
Enzyme-Linked Immunosorbent Assay
Guinea Pigs
Abdomen
Immunoglobulin A
Antibodies
Serum
Biopsy
Autoantigens
Gastroenterology
Blood Donors
Crohn Disease
Health Care Costs
transglutaminase 2
Outpatients
Morbidity
Costs and Cost Analysis
Sensitivity and Specificity

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Human recombinant tissue transglutaminase ELISA : An innovative diagnostic assay for celiac disease. / Sblattero, D.; Berti, I.; Trevisiol, C.; Marzari, R.; Tommasini, A.; Bradbury, A.; Fasano, A.; Ventura, A.; Not, T.

In: American Journal of Gastroenterology, Vol. 95, No. 5, 05.2000, p. 1253-1257.

Research output: Contribution to journalArticle

Sblattero, D. ; Berti, I. ; Trevisiol, C. ; Marzari, R. ; Tommasini, A. ; Bradbury, A. ; Fasano, A. ; Ventura, A. ; Not, T. / Human recombinant tissue transglutaminase ELISA : An innovative diagnostic assay for celiac disease. In: American Journal of Gastroenterology. 2000 ; Vol. 95, No. 5. pp. 1253-1257.
@article{e888cbef189a473f8d7aff54156194c1,
title = "Human recombinant tissue transglutaminase ELISA: An innovative diagnostic assay for celiac disease",
abstract = "OBJECTIVE: Tissue transglutaminase is the autoantigen recognized by the sera of celiac patients. An enzyme-linked immunosorbent assay (ELISA) based on guinea-pig tissue transglutaminase was recently used to measure serum tissue transglutaminase antibodies for the diagnosis of celiac disease. We determine the sensitivity and specificity of an ELISA test based on the use of human recombinant transglutaminase, compared with the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies. METHODS: Serum samples were tested from 65 patients with intestinal biopsy proven celiac disease, from 10 patients with Crohn's disease, and from 150 healthy blood donors. RESULTS: Human transglutaminase ELISA identified 64 of 65 celiac patients, whereas the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies identified 58 of 65 and 60 of 65 subjects, respectively. The three tests showed comparable specificity. CONCLUSIONS: These results proved that the human tissue transglutaminase-based ELISA represents a cost-effective strategy for identifying both symptomatic and atypical forms of celiac disease and could mean that intestinal biopsy need no longer be the gold standard for diagnosing this clinical condition. Furthermore, early identification and treatment of patients with celiac disease in an outpatient setting could have significant implications for reducing long-term morbidity and can produce major savings in future health care costs. (C) 2000 by Am. Coll. of Gastroenterology.",
author = "D. Sblattero and I. Berti and C. Trevisiol and R. Marzari and A. Tommasini and A. Bradbury and A. Fasano and A. Ventura and T. Not",
year = "2000",
month = "5",
doi = "10.1016/S0002-9270(00)00810-8",
language = "English",
volume = "95",
pages = "1253--1257",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Human recombinant tissue transglutaminase ELISA

T2 - An innovative diagnostic assay for celiac disease

AU - Sblattero, D.

AU - Berti, I.

AU - Trevisiol, C.

AU - Marzari, R.

AU - Tommasini, A.

AU - Bradbury, A.

AU - Fasano, A.

AU - Ventura, A.

AU - Not, T.

PY - 2000/5

Y1 - 2000/5

N2 - OBJECTIVE: Tissue transglutaminase is the autoantigen recognized by the sera of celiac patients. An enzyme-linked immunosorbent assay (ELISA) based on guinea-pig tissue transglutaminase was recently used to measure serum tissue transglutaminase antibodies for the diagnosis of celiac disease. We determine the sensitivity and specificity of an ELISA test based on the use of human recombinant transglutaminase, compared with the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies. METHODS: Serum samples were tested from 65 patients with intestinal biopsy proven celiac disease, from 10 patients with Crohn's disease, and from 150 healthy blood donors. RESULTS: Human transglutaminase ELISA identified 64 of 65 celiac patients, whereas the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies identified 58 of 65 and 60 of 65 subjects, respectively. The three tests showed comparable specificity. CONCLUSIONS: These results proved that the human tissue transglutaminase-based ELISA represents a cost-effective strategy for identifying both symptomatic and atypical forms of celiac disease and could mean that intestinal biopsy need no longer be the gold standard for diagnosing this clinical condition. Furthermore, early identification and treatment of patients with celiac disease in an outpatient setting could have significant implications for reducing long-term morbidity and can produce major savings in future health care costs. (C) 2000 by Am. Coll. of Gastroenterology.

AB - OBJECTIVE: Tissue transglutaminase is the autoantigen recognized by the sera of celiac patients. An enzyme-linked immunosorbent assay (ELISA) based on guinea-pig tissue transglutaminase was recently used to measure serum tissue transglutaminase antibodies for the diagnosis of celiac disease. We determine the sensitivity and specificity of an ELISA test based on the use of human recombinant transglutaminase, compared with the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies. METHODS: Serum samples were tested from 65 patients with intestinal biopsy proven celiac disease, from 10 patients with Crohn's disease, and from 150 healthy blood donors. RESULTS: Human transglutaminase ELISA identified 64 of 65 celiac patients, whereas the guinea pig transglutaminase ELISA and IgA antiendomysium antibodies identified 58 of 65 and 60 of 65 subjects, respectively. The three tests showed comparable specificity. CONCLUSIONS: These results proved that the human tissue transglutaminase-based ELISA represents a cost-effective strategy for identifying both symptomatic and atypical forms of celiac disease and could mean that intestinal biopsy need no longer be the gold standard for diagnosing this clinical condition. Furthermore, early identification and treatment of patients with celiac disease in an outpatient setting could have significant implications for reducing long-term morbidity and can produce major savings in future health care costs. (C) 2000 by Am. Coll. of Gastroenterology.

UR - http://www.scopus.com/inward/record.url?scp=0034066733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034066733&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(00)00810-8

DO - 10.1016/S0002-9270(00)00810-8

M3 - Article

C2 - 10811336

AN - SCOPUS:0034066733

VL - 95

SP - 1253

EP - 1257

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -